16928-01-1

Upstream product

• 88-18-6 2-tert-Butylphenol 
• 75-36-5 acetyl chloride 
• 3245-25-8 2-(tert-butyl)phenyl acetate 

Downstream Products

• 153356-04-8 1-[3-(tert-butyl)-4-hydroxy-5-nitrophenyl]-1-ethanone 
• 1095170-71-0 C₁₃H₁₇ClO₂ 
• 1142224-31-4 4-acetyl-2-(1,1-dimethylethyl)phenyl trifluoromethanesulfonate 
• 142651-19-2 1-(3-(tert-butyl)-4-methoxyphenyl)ethan-1-one 
• 1809653-01-7 1,3,5-tris(3’-tert-butyl-4’-hydroxy-5’-formylphenyl)benzene 
• 153356-10-6 1-(5-bromo-3-tert-butyl-4-hydroxyphenyl)ethanone 
• 153356-02-6 1-(3-tert-Butyl-4-hydroxy-5-iodophenyl)ethanone 

Relevant academic research and scientific papers

Vanadium-Catalyzed Oxidative Intramolecular Coupling of Tethered Phenols: Formation of Phenol-Dienone Products

A mild and efficient method for the vanadium-catalyzed intramolecular coupling of tethered free phenols is described. The corresponding phenol-dienone products are prepared directly in good yields with low catalyst loadings. Electronically diverse tethered phenol precursors are well tolerated, and the catalytic method was effectively applied as the key step in syntheses of three natural products and a synthetically useful morphinan alkaloid precursor.

2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST

The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.

PHARMACEUTICAL COMPOSITION, USE OF 2-IMINOPYRROLIDINE DERIVATIVE FOR PRODUCTION OF PHARMACEUTICAL COMPOSITION, AND KIT FOR TREATMENT OR AMELIORATION OF HEART DISEASES

One embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative and at least one other compound (B). Another embodiment of the present invention is a pharmaceutical composition compris

SPIROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

5-(1-Acetoxyvinyl)-cyclosaligenyl-2′,3′-dideoxy-2′, 3′- didehydrothymidine monophosphates, a second type of new, enzymatically activated cyclosaligenyl pronucleotides

In our attempt to further develop the cycloSal pronucleotide concept, we report on 5-(1-acetoxyvinyl)-cycloSal-d4TMPs as a new type of enzyme-activated pronucleotides. These compounds were converted into 5-acetyl-cycloSal-d4TMPs by (carboxy)esterase cleav

PROCESSES FOR PRODUCING CYCLIC BENZAMIDINE DERIVATIVE

In the present invention, the methods of producing a fluorinated cyclic benzamidine derivative (A), or a salt thereof, comprise the step of reacting a specific novel compound with ammonia or imide. The methods of this invention for producing a morpholine-

2-IMINOPYRROLIDINE DERIVATES

A 2-iminopyrrolidine derivative represented by the formula: {wherein ring B represents a benzene ring, pyridine ring, etc.; R101 - R103 represent hydrogen, halogen, C1-6 alkyl, etc.; R5 represents hydrogen, C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, etc.; R6 represents hydrogen, C1-6 alkyl, C1-6 alkyloxycarbonyl, etc.; Y1 represents a single bond, -CH2-, etc.; Y2 represents a single bond, -CO-, etc.; and Ar represents hydrogen, a group represented by the formula: [wherein R10-R14 represent hydrogen, C1-6 alkyl, hydroxyl, C1-6 alkoxy, etc.; and R11 and R12 or R12 and R13 may bond together to form a 5- to 8-membered heterocyclic ring], etc.}, or a salt thereof.